Cancer Immunology and Immunotherapy. Volume 1 of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy


Book
August 2021
Elsevier Science and Technology
ID: 5308596

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy�examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited.

Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches.

Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

1. The hallmarks of cancer and immunology
2. Innate and adaptive immunity in cancer
3. Inflammation and cancer
4. Novel immunotherapeutic approaches to cancer: Voltage-gated sodium channel expression in immune cells and tumors
5. Immunoediting and cancer priming
6. Metabolic reprogramming and immunity in cancer
7. Epigenetic programming of the immune responses in cancer
8. Cellular therapeutics in immuno-oncology
9. T-cell engaging bispecific antibody therapy
10. Role of microbiome in cancer immunotherapy
11. STING pathway and modulation for cancer immunotherapy
12. Oncolytic viruses in immunotherapy
13. Comparison of therapeutic strategies for immuno-oncology
14. Intrinsic and acquired cancer immunotherapy resistance
15. Preclinical and clinical toxicity of immuno-oncology agents and mitigation strategies

Authors

Mansoor M. Amiji Distinguished Professor and Chairman, Department of Pharmaceutical Sciences, School of Pharmacy, Bouve College of Health Sciences, Northeastern University, Boston, Massachusetts, USA. Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouv� College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable. Lara Scheherazade Milane Assistant Teaching Professor in Biotechnology, Bouve College of Health Sciences, Northeastern University, USA. Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouv� College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.

Table of Contents

Authors

Related Topics

Related Products

Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027

Innovation Waves in Immuno-oncology Therapy Development

Claudin 18.2-Targeted Immunotherapy: A Landscape Analysis of Stakeholders, Drug Modalities, Pipeline and Business Opportunities from An Industry Perspective

Global Cancer Immunotherapy Drugs Market by Type (Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), Indication (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-user - Forecast 2024-2030

Global Immuno-oncology Market